ZHANG Teng-long1,2,CHEN Zhi-bao1,JU Chuan-jing2,3, LI Zhong-yi2,MENG Ke-yin2,WANG Xiong1,WAN Jia-yu2
1.Science and Biology Institute, Heilongjiang Bayi Agriculture University, Daqing 163319, China; 2.Institute of Veterinary Sciences, Academy of Military Medical Science, Changchun 130062, China 3.The Forth Hospital of Jilin University, Changchun 130011, China
Abstract：Prion diseases are neurodegenerative and infectious disorders characterized by the aggregation of a misfolded isoform (PrPSc) of the cellular prion protein (PrPC). Because of its high lethality and incidence, currently, there is not a effective way to cure these diseases, which have already became one of a serious problem that threaten human and animal health. As development of technology and deeper research in neurodegenerative diseases, scientist found that autophagy, RNA interference, anti-PrP-antibody, nucleic acid vaccines and some medicine and compounds have prominent effect on the treatment of diseases. In this review, we demonstrate some methods and theories which have potential value in treating prion diseases.
[1]Collinge J. Molecular neurology of prion disease[J]. J Neurol Neurosurg Psychiatry, 2005, 76(7):906-919. DOI:10.1136/jnnp.2004.048660 [2]Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts[J]. Cell, 2004, 116(2):313-327. [3]Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain[J]. Nat Rev Microbiol, 2006, 4(3):201-211. DOI:10.1038/Nrmicro1346 [4]Wan J, Bai X, Liu W, et al. Polymorphism of prion protein gene in Arctic fox (Vulpes lagopus)[J]. Molecul Biol Reports, 2009, 36(6):1299-1303. DOI:10.1007/s11033-008-9312-6 [5]Zahn R, Guntert P, von Schroetter C, et al. NMR structure of a variant human prion protein with two disulfide bridges[J]. J Mol Biol, 2003, 326(1):225-234. [6]Riek R, Fiaux J, Bertelsen EB, et al. Solution NMR techniques for large molecular and supramolecular structures[J]. J Am Chem Soc, 2002, 124(41):12144-12153. [7]Soto C. Transmissible proteins: expanding the prion heresy[J]. Cell, 2012, 149(5):968-977. DOI:10.1016/j.cell.2012.05.007 [8]Beekes M, McBride PA. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies[J]. Febs J, 2007, 274(3):588-605. DOI:10.1111/j.1742-4658.2007.05631.x [9]Goodfield J. Cannibalism and kuru[J]. Nature, 1997, 387(6636):841. DOI:10.1038/43041 [10]Post K, Riesner D, Walldorf V, et al. Fly larvae and pupae as vectors for scrapie[J]. Lancet, 1999, 354(9194):1969-1970. DOI:10.1016/S0140-6736(99)00469-9 [11]Mathiason CK, Powers JG, Dahmes SJ, et al. Infectious prions in the saliva and blood of deer with chronic wasting disease[J]. Science, 2006, 314(5796):133-136. DOI:10.1126/science.1132661 [12]Heiseke A, Aguib Y, Schatzl HM. Autophagy, prion infection and their mutual interactions[J]. Curr Issues Mol Biol, 2010, 12: 87-97. [13]Kamada Y, Funakoshi T, Shintani T, et al. Tor-mediated induction of autophagy via an Apg1 protein kinase complex[J]. J Cell Biol, 2000, 150(6):1507-1513. [14]Levine B, Kroemer G. Autophagy in the pathogenesis of disease[J]. Cell, 2008, 132(1):27-42. DOI:10.1016/j.cell.2007.12.018 [15]Sarkar S, Davies JE, Huang Z, et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein[J]. J Biol Chem, 2007, 282(8):5641-5652. DOI:10.1074/jbc.M609532200 [16]Kroemer G, Levine B. Autophagic cell death: the story of a misnomer[J]. Nat Rev Mol Cell Biol, 2008, 9(12):1004-1010. DOI:10.1038/nrm2529 [17]Berger Z, Ravikumar B, Menzies FM, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins[J]. Human Mol Gen, 2006, 15(3):433-442. DOI:10.1093/hmg/ddi458 [18]Fimia GM, Stoykova A, Romagnoli A, et al. Ambra1 regulates autophagy and development of the nervous system[J]. Nature, 2007, 447(7148):1121-1125. DOI:10.1038/nature05925 [19]Bjorkoy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death[J]. J Cell Biol, 2005, 171 (4):603-614. DOI:10.1083/jcb.200507002 [20]Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy - a novel beta-amyloid peptide-generating pathway activated in Alzheimer’s disease[J]. J Cell Biol, 2005, 171(1):87-98. DOI:10.1083/jcb.200505082 [21]Mallucci GR, Ratte S, Asante EA, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration[J]. EMBO J, 2002, 21(3):202-210. DOI:10.1093/emboj/21.3.202 [22]Orban PC, Chui D, Marth JD. Tissue- and site-specific DNA recombination in transgenic mice[J]. Proc Nat Acad Sci U S A, 1992, 89(15):6861-6865. [23]Sokol DL, Murray JD. Antisense and ribozyme constructs in transgenic animals[J]. Transg Res, 1996, 5(6):363-371. [24]Sontheimer EJ, Carthew RW. Silence from within: Endogenous siRNAs and miRNAs[J]. Cell, 2005, 122(1):9-12. DOI:10.1016/j.cell.2005.06.030 [25]Tilly G, Chapuis J, Vilette D, et al. Efficient and specific down-regulation of prion protein expression by RNAi[J]. Biochem Biophys Res Commun, 2003, 305(3):548-551. [26]Pankiewicz J, Prelli F, Sy MS, et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies[J]. Europ J Neurosci, 2006, 23(10):2635-2647. DOI:10.1111/j.1460-9568.2006.04805.x [27]White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease[J]. Nature, 2003, 422(6927):80-83. DOI:10.1038/nature01457 [28]Han YL, Li Y, Song J, et al. Immune responses in wild-type mice against prion proteins induced using a DNA prime-protein boost strategy[J]. Biomed Environ Sci, 2011, 24(5):523-529. DOI:10.3967/0895-3988.2011.05.011 [29]Sethi S, Lipford G, Wagner H, et al. Postexposure prophylaxis against prion disease with a stimulator of innate immunity[J]. Lancet, 2002, 360(9328):229-230. DOI:10.1016/S0140-6736(02)09513-2 [30]Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation[J]. J Virol, 2000, 74(10):4894-4897. DOI:10.1128/Jvi.74.10.4894-4897.2000 [31]Korth C, May BCH, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease[J]. Proce Nat Acad Sci U S A, 2001, 98(17):9836-9841. DOI:10.1073/pnas.161274798 [32]Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease[J]. Dement Geriatr Cogn, 2004, 17(3):158-163. DOI:10.1159/000076350 [33]Ishikawa K, Kudo Y, Nishida N, et al. Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies[J]. J Neurochem, 2006, 99(1):198-205. DOI:10.1111/j.1471-4159.2006.04035.x [34]Cordeiro Y, Lima LM, Gomes MP, et al. Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,4’-dianilino-1,1’-binaphthyl-5,5′-sulfonate (bis-ANS)[J]. J Biol Chem, 2004, 279(7):5346-5352. DOI:10.1074/jbc.M312262200 [35]Supattapone S, Nguyen HO, Cohen FE, et al. Elimination of prions by branched polyamines and implications for therapeutics[J]. Proceed Nat Acad Sci U S A, 1999, 96(25):14529-14534.
2015, Vol. 31 
